Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.
<h4>Background & aims</h4>The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the respo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093620&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850026575664250880 |
|---|---|
| author | Shan-shan Su Huan He Ling-bo Kong Yu-guo Zhang Su-xian Zhao Rong-qi Wang Huan-wei Zheng Dian-xing Sun Yue-min Nan Jun Yu |
| author_facet | Shan-shan Su Huan He Ling-bo Kong Yu-guo Zhang Su-xian Zhao Rong-qi Wang Huan-wei Zheng Dian-xing Sun Yue-min Nan Jun Yu |
| author_sort | Shan-shan Su |
| collection | DOAJ |
| description | <h4>Background & aims</h4>The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.<h4>Methods</h4>Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in patients at baseline, 12 and 24 weeks following treatment and in 20 healthy controls.<h4>Results</h4>Frequencies of Tregs, PD-1 and TLR3 expressing cells were higher in patients than those in control subjects (P<0.05). Patients with complete early virological response (cEVR) showed lower Tregs, PD-1 expressing CD4+ or CD8+ T-cells than those without cEVR at 12 weeks (P<0.05). Patients with low TLR3 expressing CD14+ monocytes at baseline had a high rate of cEVR (P<0.05).<h4>Conclusions</h4>Low peripheral TLR3 expressing CD14+ monocytes at baseline could serve as a predictor for cEVR of antiviral therapy in chronic HCV-infected patients. The cEVR rates were significantly increased in the patients with reduced circulating Tregs, PD-1 expressing CD4+ or CD8+ T-cells.<h4>Trial registration</h4>Chinese Clinical Trial Registry ChiCTR10001090. |
| format | Article |
| id | doaj-art-a3a3c466337d490fac562d1b565fdfe8 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-a3a3c466337d490fac562d1b565fdfe82025-08-20T03:00:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9362010.1371/journal.pone.0093620Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.Shan-shan SuHuan HeLing-bo KongYu-guo ZhangSu-xian ZhaoRong-qi WangHuan-wei ZhengDian-xing SunYue-min NanJun Yu<h4>Background & aims</h4>The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.<h4>Methods</h4>Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in patients at baseline, 12 and 24 weeks following treatment and in 20 healthy controls.<h4>Results</h4>Frequencies of Tregs, PD-1 and TLR3 expressing cells were higher in patients than those in control subjects (P<0.05). Patients with complete early virological response (cEVR) showed lower Tregs, PD-1 expressing CD4+ or CD8+ T-cells than those without cEVR at 12 weeks (P<0.05). Patients with low TLR3 expressing CD14+ monocytes at baseline had a high rate of cEVR (P<0.05).<h4>Conclusions</h4>Low peripheral TLR3 expressing CD14+ monocytes at baseline could serve as a predictor for cEVR of antiviral therapy in chronic HCV-infected patients. The cEVR rates were significantly increased in the patients with reduced circulating Tregs, PD-1 expressing CD4+ or CD8+ T-cells.<h4>Trial registration</h4>Chinese Clinical Trial Registry ChiCTR10001090.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093620&type=printable |
| spellingShingle | Shan-shan Su Huan He Ling-bo Kong Yu-guo Zhang Su-xian Zhao Rong-qi Wang Huan-wei Zheng Dian-xing Sun Yue-min Nan Jun Yu Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. PLoS ONE |
| title | Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. |
| title_full | Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. |
| title_fullStr | Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. |
| title_full_unstemmed | Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. |
| title_short | Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. |
| title_sort | regulatory phenotype pd 1 and tlr3 expression in t cells and monocytes from hcv patients undergoing antiviral therapy a randomized clinical trial |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093620&type=printable |
| work_keys_str_mv | AT shanshansu regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT huanhe regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT lingbokong regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT yuguozhang regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT suxianzhao regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT rongqiwang regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT huanweizheng regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT dianxingsun regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT yueminnan regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial AT junyu regulatoryphenotypepd1andtlr3expressionintcellsandmonocytesfromhcvpatientsundergoingantiviraltherapyarandomizedclinicaltrial |